Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F.
Clin Cancer Res. 2023 Nov 1;29(21):4385-4398. doi: 10.1158/1078-0432.CCR-23-0103.
ARID1A loss activates MAPK signaling via DUSP4 downregulation.
Mandal J, Yu ZC, Shih IM, Wang TL.
J Biomed Sci. 2023 Dec 9;30(1):94. doi: 10.1186/s12929-023-00985-5.
Synchronous bilateral primary ovarian cancer with right endometroid carcinoma and left high-grade serous carcinoma: a case report and literature review.
Fujimori M, Takahashi T, Furukawa Y, Takanashi A, Iizawa Y, Jimbo M, Soeda S, Fujimori K, Takeichi K.
BMC Womens Health. 2022 Apr 5;22(1):103. doi: 10.1186/s12905-022-01684-3.
Gynecological tumor triplicity.
Mladěnka A, Šimetka O, Mladěnka P, Klát J.
Ceska Gynekol. 2018 Winter;83(6):445-447.
Ovarian endometroid adenocarcinoma in pregnancy.
Zivanović A, Dimitrijević A, Kastratović T, Djurić J, Stanković V, Tanasković I.
Vojnosanit Pregl. 2011 Feb;68(2):181-4. doi: 10.2298/vsp1102181z.
Systemic therapy for non-serous ovarian carcinoma.
Chávarri-Guerra Y, González-Ochoa E, De-la-Mora-Molina H, Soto-Perez-de-Celis E.
Chin Clin Oncol. 2020 Aug;9(4):52. doi: 10.21037/cco-20-36. Epub 2020 Jul 28.
Ribosomal S6 kinase 4 (RSK4) tumor suppressor gene promoter methylation status in ovarian cancer.
Arechavaleta-Velasco F, Dominguez-Lopez P, Acosta-Jimenez E, Diaz-Cueto L.
Mol Biol Rep. 2023 Aug;50(8):6863-6870. doi: 10.1007/s11033-023-08609-9. Epub 2023 Jul 4.
Detection and Genotyping of Human Papillomavirus (HPV16/18), Epstein-Barr Virus (EBV), and Human Cytomegalovirus (HCMV) in Endometrial Endometroid and Ovarian Cancers.
Grabarek BO, Ossowski P, Czarniecka J, Ożóg M, Prucnal J, Dziuba I, Ostenda A, Dziobek K, Boroń D, Peszek W, Kras P, Januszyk S, Dąbala M, Kasela T, Opławski M.
Pathogens. 2023 Mar 1;12(3):397. doi: 10.3390/pathogens12030397.
Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
Krepinska E, Kriz JT, Laco J.
Eur J Gynaecol Oncol. 2010;31(5):584-5.
Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
